Cara Therapeutics reported $-27749000 in Pre-Tax Profit for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Pre Tax Profit Change
Acadia Pharmaceuticals ACAD:US $ -112.57M 69.67M
Acelrx Pharmaceuticals ACRX:US $ -8.67M 0.76M
Cara Therapeutics CARA:US $ -27749000 5.63M
Chugai Pharma 4519:JP Y 186206M 47766M
Halozyme Therapeutics HALO:US $ 81.63M 20.43M
JAZZ PHA JAZZ:US $ 321.29M 19.04M
Johnson & Johnson JNJ:US $ 8218M 1879M
Neurocrine Biosciences NBIX:US $ 21.4M 35.2M
Pacira Pharmaceuticals PCRX:US $ 39.79M 19.7M
Pain Therapeutics PTIE:US $ -17.53M 3.36M
Pfizer PFE:US $ 11328M 4083M
Redhill Biopharma RDHL:US $ -24.37M 6.97M
Revance Therapeutics RVNC:US $ -64.34M 1.24M
Supernus Pharmaceuticals SUPN:US $ 14.72M 12.67M
Teva Pharmaceutical Industries TEVA:US $ 766M 253M
Vanda Pharmaceuticals VNDA:US $ -7.56M 16.17M